[go: up one dir, main page]

WO2018144093A3 - Formulations for improved skin care - Google Patents

Formulations for improved skin care Download PDF

Info

Publication number
WO2018144093A3
WO2018144093A3 PCT/US2017/059960 US2017059960W WO2018144093A3 WO 2018144093 A3 WO2018144093 A3 WO 2018144093A3 US 2017059960 W US2017059960 W US 2017059960W WO 2018144093 A3 WO2018144093 A3 WO 2018144093A3
Authority
WO
WIPO (PCT)
Prior art keywords
hyaluronic acid
collagen
formulations
skin care
improved skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/059960
Other languages
French (fr)
Other versions
WO2018144093A2 (en
Inventor
Mark A. Pinsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2018144093A2 publication Critical patent/WO2018144093A2/en
Publication of WO2018144093A3 publication Critical patent/WO2018144093A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/738—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/001—Preparations for care of the lips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne des compositions et des procédés d'administration de collagène et/ou d'acide hyaluronique à un sujet humain. Les vésicules lipidiques contenant du collagène et/ou de l'acide hyaluronique de l'invention fournissent un système d'administration de protéine de collagène et/ou d'acide hyaluronique qui améliore significativement l'état de la peau d'un sujet humain tout en éliminant les problèmes associés à l'instabilité chimique et physique du collagène et/ou de l'acide hyaluronique ainsi que des réponses immunitaires associées.The present invention relates to compositions and methods for delivering collagen and / or hyaluronic acid to a human subject. The lipid vesicles containing collagen and / or hyaluronic acid of the invention provide a system for delivery of collagen and / or hyaluronic acid protein that significantly improves the skin condition of a human subject while eliminating the problems associated with the chemical and physical instability of collagen and / or hyaluronic acid as well as associated immune responses.

PCT/US2017/059960 2016-11-03 2017-11-03 Formulations for improved skin care Ceased WO2018144093A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662416987P 2016-11-03 2016-11-03
US62/416,987 2016-11-03

Publications (2)

Publication Number Publication Date
WO2018144093A2 WO2018144093A2 (en) 2018-08-09
WO2018144093A3 true WO2018144093A3 (en) 2019-03-07

Family

ID=63040032

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/059960 Ceased WO2018144093A2 (en) 2016-11-03 2017-11-03 Formulations for improved skin care

Country Status (1)

Country Link
WO (1) WO2018144093A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
JP7492918B2 (en) 2018-06-04 2024-05-30 アーキュティス・バイオセラピューティクス・インコーポレーテッド Methods and formulations for improving roflumilast skin permeation lag time
TW202042785A (en) * 2019-04-01 2020-12-01 美商格爾托公司 Topical formulations of recombinant collagens
SG11202111349QA (en) 2019-04-12 2021-11-29 Geltor Inc Recombinant elastin and production thereof
US20200405621A1 (en) * 2019-06-28 2020-12-31 The Procter & Gamble Company Skin Care Composition
US11786451B2 (en) 2019-06-28 2023-10-17 The Procter & Gamble Company Skin care composition
EP4004190A4 (en) * 2019-07-26 2023-11-22 Pandorum Technologies Private Limited Bioengineered formulation, process for preparing and implementations thereof
EP3968948A1 (en) * 2019-07-29 2022-03-23 Giuliani S.p.A. Cosmetic composition with combined filler and skin regenerative effect
WO2021056106A1 (en) 2019-09-23 2021-04-01 Dds Research Inc. Lipid vesicle compositions with penetration enhancing agents
CN111036156A (en) * 2020-01-14 2020-04-21 江苏罗格斯生物科技有限公司 Preparation method of green functional factor accurate control material
CN111281840B (en) * 2020-02-13 2022-03-29 广州伊尔美生物科技有限公司 Skin brightening and beautifying cream and preparation method thereof
MX2022008735A (en) * 2020-05-07 2022-09-19 Arcutis Biotherapeutics Inc Treatment of skin conditions using high krafft temperature anionic surfactants.
CN111494233B (en) * 2020-06-02 2023-07-14 康珞生物科技（武汉）有限公司 Preparation method and application of collagen short peptide liposome
CN112057351B (en) * 2020-09-22 2023-01-24 西安诗莱梦特生物科技有限公司 Hyaluronic acid-hydroxypropyl methyl cellulose composite hydrogel and preparation method and application thereof
CN116669696A (en) * 2020-09-30 2023-08-29 格尔托公司 Compositions comprising collagen or elastin polypeptides in combination with active ingredients and methods of use thereof
EP4221679A4 (en) * 2020-09-30 2025-03-26 Geltor, Inc. Compositions comprising combinations of collagen or elastin polypeptides with active ingredients and methods of using same
JP7386353B2 (en) 2020-12-04 2023-11-24 アーキュティス・バイオセラピューティクス・インコーポレーテッド Topical roflumilast preparations with antifungal properties
CN114246818A (en) * 2021-03-08 2022-03-29 山东祥隆医药研究院有限公司 Essence milk with allergy preventing, moisturizing and repairing effects and preparation method thereof
JP2024511215A (en) * 2021-03-24 2024-03-12 ジーエルオー ファーマ，インク． Multisomal lipid vesicles for delivery of cosmetic agents
EP4313100A4 (en) 2021-03-24 2025-10-15 Glo Pharma Inc PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION
US12144802B2 (en) 2022-09-15 2024-11-19 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug
US20240216262A1 (en) * 2022-12-29 2024-07-04 Mary Kay Inc. Cosmetic compositions and methods of using same
CN116617146B (en) * 2023-05-26 2024-12-17 广东巴松那生物科技有限公司 Skin cream for repairing hormonal face and preparation method thereof
CN117137840A (en) * 2023-09-07 2023-12-01 河北纳科生物科技有限公司 Recombinant collagen white oil biphase essential oil and preparation method thereof
CN117017869B (en) * 2023-09-15 2024-01-30 名宇(广东)化妆品科技有限公司 Whitening and freckle-removing cream and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846561A (en) * 1991-02-14 1998-12-08 Baxter International Inc. Method of binding collagen recognizing substances to liposomes
US6992172B1 (en) * 1999-11-12 2006-01-31 Fibrogen, Inc. Recombinant gelatins
US20100221319A1 (en) * 2005-10-03 2010-09-02 Pinsky Mark A Compositions and Methods for Improved Skin Care
KR20110036664A (en) * 2009-10-02 2011-04-08 가부시키가이샤 페이스 Cosmetic base consisting of collagen-modified liposomes and skin cosmetics containing same
CN102988200A (en) * 2012-12-10 2013-03-27 北京莱米瑞克科技发展有限公司 Liposome face-nourishing skin care product

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846561A (en) * 1991-02-14 1998-12-08 Baxter International Inc. Method of binding collagen recognizing substances to liposomes
US6992172B1 (en) * 1999-11-12 2006-01-31 Fibrogen, Inc. Recombinant gelatins
US20100221319A1 (en) * 2005-10-03 2010-09-02 Pinsky Mark A Compositions and Methods for Improved Skin Care
KR20110036664A (en) * 2009-10-02 2011-04-08 가부시키가이샤 페이스 Cosmetic base consisting of collagen-modified liposomes and skin cosmetics containing same
CN102988200A (en) * 2012-12-10 2013-03-27 北京莱米瑞克科技发展有限公司 Liposome face-nourishing skin care product

Also Published As

Publication number Publication date
WO2018144093A2 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
WO2018144093A3 (en) Formulations for improved skin care
WO2009086504A3 (en) Collagen formulations for improved skin care
TN2019000099A1 (en) ANTI-LAG-3 ANTIBODIES AND COMPOSITIONS
CY1120264T1 (en) LIQUID PREPARATION FOR INHALATION CONTAINING RPL554
SG10201909093XA (en) Mixed allergen compositions and methods for using the same
BR112013026706A2 (en) nutritional compositions comprising alpha hydroxy isocaproic acid
CY1115991T1 (en) PHARMACEUTICAL PARTICULAR COMPOSITION CONTAINING A DISTRIBUTION OF VITAMIN D PRODUCT AND A CORTICOSTEROID
GT200500254A (en) PROCESS FOR THE CONCENTRATION OF ANTIBODIES AND RELATED THERAPEUTIC PRODUCTS.
CY1118934T1 (en) PREPARATION OF EXTREMELY PHOSPHORLILENED N-ACETYLGACTOZAMINE-6-SULFATHASE ACTIVITY AND USES thereof
FR2944448B1 (en) STABLE PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE MONODONAL ANTIBODY AND AT LEAST ONE AMPHIPHILIC POLYSACHARIDE COMPRISING SUBSTITUENTS DERIVED FROM HYDROFOB ALCOHOLS OR HYDROPHOBIC AMINES.
UA106074C2 (en) 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
MA43404A (en) COMPOSITIONS AND METHODS OF EXPRESSION OF MULTIPLE BIOLOGICALLY ACTIVE POLYPEPTIDES FROM A SINGLE VECTOR FOR THE TREATMENT OF CONDITIONS AND OTHER HEART DISEASES
Jayaprakash et al. Curcumin potentiates α7 nicotinic acetylcholine receptors and alleviates autistic-like social deficits and brain oxidative stress status in mice
MA33295B1 (en) NEW FORMULATION OF DICLOFENAC
MA39342B2 (en) Il -21 antibody
UY32691A (en) 1H-IMIDAZO- [4,5-C] -QUINOLINONA COMPOUNDS
BR112021024632A2 (en) Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administration
CL2013003298A1 (en) Use of methotrexate because it is used to prepare a medicine, useful in the treatment of diseases that need treatment with a therapeutic product that produces autoimmunity, administered in a single cycle.
MA41150B1 (en) Proton-binding polymers for oral administration
IN2014DN03213A (en)
MX364800B (en) Improved long-acting tilmicosin and use thereof in the treatment of bovine respiratory disease complex (brdc) and in the dry cow period.
Beijnen et al. Vaccine-induced CD8+ T cell responses in children: A review of age-specific molecular determinants contributing to antigen cross-presentation
BR112018015367A2 (en) nanofiber oromucosal carriers for therapeutic treatment
BR112014027653A2 (en) formulations for the release of active ingredients
BR112015005285A2 (en) mouthwashes and tooth sensitivity treatment compositions

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17895323

Country of ref document: EP

Kind code of ref document: A2